By VETTAPHARMA reporter – Derek Roche: Novartis presented new long-term data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showing that Scemblix (asciminib) continued to deliver superior efficacy with a favorable safety and tolerability profile through Week 144 in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). The findings represent the longest follow-up reported from the pivotal Phase III ASC4FIRST trial.
The updated analysis demonstrated that major molecular response (MMR) rates continued to improve over time and remained superior with Scemblix compared with investigator-selected standard-of-care tyrosine kinase inhibitors (TKIs), including imatinib, nilotinib, dasatinib, and bosutinib. The results build upon previously reported Week 48 and Week 96 findings that established Scemblix as the first CML therapy to demonstrate superior efficacy alongside a favorable safety and tolerability profile versus standard frontline TKIs.
ASC4FIRST is a global Phase III randomized trial evaluating Scemblix as first-line therapy in newly diagnosed Ph+ CML-CP. Earlier analyses showed MMR rates of 67.7% versus 49.0% at Week 48 and 74.1% versus 52.0% at Week 96 for Scemblix and investigator-selected TKIs, respectively. The Week 144 update demonstrated continued separation between treatment arms, supporting the durability of response achieved with the STAMP inhibitor.
Scemblix is the first approved therapy that specifically targets the ABL myristoyl pocket, a mechanism known as STAMP (Specifically Targeting the ABL Myristoyl Pocket). This differentiated mechanism contrasts with conventional ATP-competitive TKIs that have formed the backbone of CML treatment for more than two decades.
Beyond molecular response improvements, Novartis reported that the favorable safety and tolerability profile observed in earlier analyses remained consistent through long-term follow-up. Previous ASC4FIRST analyses demonstrated fewer grade 3 or higher adverse events, fewer dose modifications, and substantially lower treatment discontinuation rates compared with standard-of-care TKIs.
Chronic myeloid leukemia is a rare blood cancer driven by the BCR::ABL1 fusion gene. Although current TKIs have transformed long-term outcomes, many patients discontinue treatment because of intolerance or fail to achieve deep molecular responses that may support long-term disease control and potential treatment-free remission strategies.
The ASCO presentation further strengthens Novartis’ position in the CML market, where the company has maintained a leadership presence for more than two decades. Long-term superiority over standard frontline TKIs may support broader adoption of Scemblix as physicians increasingly prioritize both efficacy and tolerability when selecting initial therapy for newly diagnosed patients.
For patients, the findings suggest that Scemblix may provide more durable molecular responses while maintaining a favorable tolerability profile over extended treatment periods. From a commercial perspective, continued long-term differentiation could strengthen Scemblix’s growth trajectory as Novartis expands its presence in the frontline CML market.
Quick FAQs
1. What Is Scemblix?
Scemblix (asciminib) is a STAMP inhibitor that specifically targets the ABL myristoyl pocket and is approved for treating Philadelphia chromosome-positive chronic myeloid leukemia.
2. What Did Novartis Present at ASCO 2026?
Novartis presented Week 144 follow-up data from the Phase III ASC4FIRST trial showing continued superior efficacy and favorable safety and tolerability of Scemblix in newly diagnosed CML patients.
3. What Is the ASC4FIRST Study?
ASC4FIRST is a global Phase III trial evaluating Scemblix versus investigator-selected standard-of-care TKIs in adults with newly diagnosed Ph+ CML-CP.
4. What Is Chronic Myeloid Leukemia?
CML is a blood cancer driven by the BCR::ABL1 fusion gene that causes uncontrolled growth of abnormal white blood cells.
5. What Makes Scemblix Different From Other CML Therapies?
Scemblix is the first approved STAMP inhibitor and works by targeting the ABL myristoyl pocket rather than the ATP-binding site targeted by conventional TKIs.
6. Why Are the Week 144 Results Important?
The data provide the longest follow-up from ASC4FIRST and demonstrate durable efficacy and consistent tolerability benefits over standard frontline CML therapies.
